@article{5a32499131bb4fd6bf0b4c32f845b5e3,
title = "GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses",
abstract = "Certain chemotherapeutics elicit potent anti-tumor immunity. Kashyap et al. demonstrate that microtubule-destabilizing chemotherapeutics induce maturation of dendritic cells through activation of microtubule-associated protein GEF-H1. This leads to effective priming of CD8 T cells against tumor antigens. GEF-H1 is critical for anti-tumor immunity of microtubule-targeting chemotherapy.",
keywords = "GEF-H1, JNK pathway, ansamitocin-P3, chemotherapy, cross presentation, dendritic cells, immunotherapy, lfc, microtubule-targeting agents, plinabulin",
author = "Kashyap, {Abhishek S.} and Laura Fernandez-Rodriguez and Yun Zhao and Gianni Monaco and Trefny, {Marcel P.} and Naohiro Yoshida and Kea Martin and Ashwani Sharma and Natacha Olieric and Pankaj Shah and Michal Stanczak and Nicole Kirchhammer and Park, {Sung Moo} and Sebastien Wieckowski and Heinz Laubli and Rachid Zagani and Benjamin Kasenda and Steinmetz, {Michel O.} and Reinecker, {Hans Christian} and Alfred Zippelius",
note = "Funding Information: We are grateful to Prof. Karl-Heinz Altmann for providing CW190. This work was supported by grants from the NIH ( AI113333 , DK068181 , and DK043351 to H.-C.R.); the Cancer League Switzerland ( KFS-3394-02-2014 to A.Z.); the Huggenberger Foundation and Swiss National Science Foundation ( IZK0Z3_170718 to A.S.K.); and the Swiss National Science Foundation ( 31003A_166608 to M.O.S.). Further financial support was received from BeyondSpring Inc. (to M.O.S. and A.Z.). Funding Information: We are grateful to Prof. Karl-Heinz Altmann for providing CW190. This work was supported by grants from the NIH (AI113333, DK068181, and DK043351 to H.-C.R.); the Cancer League Switzerland (KFS-3394-02-2014 to A.Z.); the Huggenberger Foundation and Swiss National Science Foundation (IZK0Z3_170718 to A.S.K.); and the Swiss National Science Foundation (31003A_166608 to M.O.S.). Further financial support was received from BeyondSpring Inc. (to M.O.S. and A.Z.). A.S.K. H.-C.R. and A.Z. designed the study and wrote the manuscript with contributions from all authors. A.S.K. led and performed most experiments with advice from H.-C.R. and A.Z. Y.Z. K.M. and S.W. helped with coimmunoprecipitation, western immunoblotting, and cell imaging and culture. L.F.-R. N.Y. K.M. P.S. and H.L. helped with flow cytometry and animal studies. A.S. and N.O. performed in vitro microtubule-binding experiments. M.O.S. provided reagents and guidance for experiments with the various microtubule-targeting agents and in vitro microtubule-binding assays. N.K. and M.S. helped with generation of GEF-H1?/? cells and functional validation. G.M. M.P.T. S.-M.P. and H.-C.R. performed RNA-seq and its analyses. B.K. and G.M. performed TCGA survival analyses and B.K. performed meta-analysis. R.Z. performed mice tumor experiments with guidance from A.S.K. H.-C.R. and A.Z. All authors read and reviewed the manuscript. The authors declare no competing interests. Publisher Copyright: {\textcopyright} 2019 The Author(s)",
year = "2019",
month = sep,
day = "24",
doi = "10.1016/j.celrep.2019.08.057",
language = "English (US)",
volume = "28",
pages = "3367--3380.e8",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "13",
}